Prøve GULL - Gratis
Addressing a Market Gap: The Case for 'Make in India' Dialysis
Mint Mumbai
|October 09, 2025
Chronic Kidney Disease (CKD) is rapidly emerging as a major public health challenge in India, imposing a significant economic burden on individuals and the healthcare system.
-
This growing epidemic is fuelled by the rising incidences of diabetes and hypertension—two primary risk factors for kidney disease.
The result is a ballooning number of patients who will eventually require dialysis, a lifesaving but costly procedure. This presents a critical challenge to the nation’s healthcare infrastructure, a problem compounded by significant market failure: India's heavy reliance on imported dialysis machines.
THE IMPORT DEPENDENCY TRAP
Currently, the vast majority of dialysis machines used in India are imported. This dependence creates several economic and logistical hurdles:
• High Capital Costs: Imported machines are expensive, making it financially challenging for hospitals, especially in Tier-2 and Tier-3 cities, to establish or expand dialysis centres.
Denne historien er fra October 09, 2025-utgaven av Mint Mumbai.
Abonner på Magzter GOLD for å få tilgang til tusenvis av kuraterte premiumhistorier og over 9000 magasiner og aviser.
Allerede abonnent? Logg på
FLERE HISTORIER FRA Mint Mumbai
Mint Mumbai
Europe bets on $25 bn space budget amid defence hike
Europe’s equivalent of NASA is seeking €22 billion ($25.
1 min
November 27, 2025
Mint Mumbai
China’s ‘McNuggetization’: It’s beneficial for the environment
A wide-scope dietary shift in China is doing the planet a good turn
3 mins
November 27, 2025
Mint Mumbai
Flexi-cap funds in focus as smids falter
A silent pivot
3 mins
November 27, 2025
Mint Mumbai
Labour codes: Focus on empathy and not just efficiency
The consolidation of 29 archaic labour laws into four comprehensive new codes—on wages, social security, industrial relations and occupational safety—is among the most significant structural reforms undertaken by India in the post-liberalization era.
3 mins
November 27, 2025
Mint Mumbai
These firms will sell shovels during semaglutide gold rush
Weight-loss drug semaglutide, also used to treat type-2 diabetes, will face its next big turning point in early 2026, when patents held by Novo Nordisk expire in India.
2 mins
November 27, 2025
Mint Mumbai
HC to hear Apple's plea on fine in Dec
Apple is challenging the new penalty math formula in India's competition law.
1 min
November 27, 2025
Mint Mumbai
Climate crisis: Innovation works, compression doesn't
After weeks of hot air, the UN’s CoP summit limped to an end in Brazil's Amazonian hub of Belém over the weekend, with a ‘deal’ that delivers nothing measurable for the climate, while wasting political capital and much effort on pledges.
3 mins
November 27, 2025
Mint Mumbai
MO Alternates launches its maiden private credit fund
The %3,000 crore fund has drawn capital from family offices, ultra-HNIs and institutions
3 mins
November 27, 2025
Mint Mumbai
Kharif grain production likely to rise to 173 mt
India's kharif foodgrain output is expected to rise to 173.
1 min
November 27, 2025
Mint Mumbai
IL&FS group repays ₹48,463 cr loan
Debt-ridden IL&FS group has repaid ₹48,463 crore to its creditors as of September 2025, out of the total ₹61,000 crore debt resolution target, as per the latest status report filed before insolvency appellate tribunal NCLAT.
1 min
November 27, 2025
Listen
Translate
Change font size

